2019 Hepatitis C Genotypes and Treatment

2019 HCV Genotypes and Treatment
Offered on this page is news and research articles with a focus on treating HCV according to genotype using FDA approved medicines. Information is extracted from news articles, peer-reviewed journals, as well as liver meetings/conferences, research manuscripts and interactive learning activities.

Research Articles
Current full-text articles covering every aspect of HCV

HCV Guidance Updates
The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America with the International Antiviral Society developed a living document with ever evolving guidelines to treat HCV

The following pages include guidance for management of  treatment-naive patients.
Genotype 1 
Genotype 2 
Genotype 3 
Genotype 4 
Genotype 5 or 6

The following pages include guidance for management of treatment-experienced patients.
Genotype 1 
Genotype 2 
Genotype 3 
Genotype 4 
Genotype 5 or 6 

Stay current with all guideline updates, "click here."

March 2019
Mar 11
Glecaprevir and Pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study.

Glecaprevir/Pibrentasvir Unaffected by Acid-Reducing Drugs for Hepatitis C
A new analysis of multiple studies with glecaprevir/pibrentasvir (G/P; Mavyret) confirms that pan-genotypic efficacy for hepatitis C virus (HCV) is achieved regardless of whether patients are concurrently receiving gastric acid-reducing drugs.

February 2019
Feb 26, 2019
Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification 

Feb 21, 2019
Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy
At support of our hypothesis, some studies report small HCV outbreaks in Europe due to breaches in standards of health and safety practices among health-care workers [56]. Indeed, an interesting case–control study highlighted some unconventional routes of diffusion of Hepatitis C infection such as digestive endoscopy, beauty treatments and professional pedicure/manicure [57]. This suggest not only a necessary evaluation of the safety practices in surgery, but the fundamental importance of not lowering the safety levels, especially among all health-care professionals.

Genotype 1b is still the most prevalent, even if shows a significantly increase in the under 40 years old population. Instead, genotype 3a seems to have a moderate increase among young people. Overall, the alarming finding is the “returning” role of the iatrogenic transmission as risk factor for the diffusion of Hepatitis C infection.

Feb 14, 2019
Of Interest
Direct-acting antivirals reduce risk of premature mortality and liver cancer for people with chronic hepatitis C 

A 6-Week Direct-Acting Antiviral Regimen for Chronic HCV Infection
Atif Zaman, MD, MPH reviewing Zeuzem S et al. Hepatology 2019 Jan 28
Phase IIb data show promising safety and efficacy of a 6-week, three-drug regimen in selected patients.

Feb 9, 2019
Mavyret - Safety and efficacy in patients receiving opioid substitution therapy/HCV genotypes 1-6

Feb 6, 2019
Treat All - Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore
Hepatitis C virus (HCV) infection is a major public health issue among people who inject drugs (PWID) with prevalence of 50–80% in the United States. Effective, simple, oral direct acting agents (DAA) of short duration with minimal side effects have been associated with cure rates > 95%.

Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients.

 Of Interest
Feb 6, 2019
2019 Hepatitis C - Testing, Treatment Options, Stages of fibrosis and Care

January 2019
The recent discovery of 3 new strains of hepatitis C virus (HCV) genotype (GT) 7 in Africa, shortly after GT 8 was identified in India, pose challenges to attaining the World Health Organization (WHO) goal of eradicating HCV globally by 2030. Manjinder Sandhu, PhD, Senior Group Leader, Wellcome Sanger Institute, Hinxton, Cabridgeshire, UK and a senior author of the study uncovering the new GT 7 subtypes, noted the strains had mutations associated with resistance to some direct-acting antivirals (DAAs), and called for increased clinical research in these under-resourced areas to facilitate development of effective interventions...

January 17, 2019

Jan 11, 2019
Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men

Ledipasvir Plus Sofosbuvir Safe, Effective in Children Age 6 to 12

Jan 9, 2019
Genotype 3
Hepatitis C Genotype 3 Treated with Shortened Glecapravir/Pibrentasvir 

Of Interest
Jan 2, 2019
Haruki Uojima, Shuzo Kobayashi, Hisashi Hidaka, Takeshi Kinbara, Tomoaki Fujikawa, Tsuyoshi Nakayama, Hiroki Yamanoue, Takayuki Kanemaru, Tohru Hashimoto, Ji Hyun Sung, Makoto Kako, Wasaburo Koizumi 

Annals Of Hepatology

Genotype 4
Abdel-Moneim A, et al. Ann Gastroenterol. 2019

Genotype 4
New HCV genotype subtypes present in sub-Saharan Africa

No comments:

Post a Comment